ClinicalTrials.gg
CompletedNCT02251145Updated Sep 29, 2014

Effects of Tipranavir (TPV) and Ritonavir (RTV) on the Pharmacokinetic Characteristics of Tenofovir Disoproxil Fumarate in Healthy Volunteers

A Phase 1 interventional study of Tipranavir low dose and Tipranavir high dose in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-09-29.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Study to characterise the effects of two dose combinations of tipranavir/ritonavir (TPV 500 mg/RTV 100 mg and TPV 750 mg/RTV 200 mg) administered BID, on the pharmacokinetics of tenofovir disoproxil fumarate as well as the effects of tenofovir disoproxil fumarate on the pharmacokinetics of tipranavir/ritonavir.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability and willingness to give written in accordance with institutional and regulatory guidelines and to comply with the nature of the study and the related requirements
  2. Healthy males or females between 18 and 60 years of age inclusive
  3. A >18.5 and \<30 kg/m2
  4. Ability to swallow numerous large capsules without difficulty
  5. Reasonable probability for completion of the study, in the opinion of the investigator
  6. Acceptable laboratory values that indicate adequate baseline organ function are required at the time of screening. Laboratory values are considered to be acceptable if severity \<= Grade1 based on the AIDS Clinical Trials Group (ACTG) Division of AIDS (DAIDS) Grading Scale. All abnormal laboratory values > Grade 1 (e.g., creatine phosphokinase (CPK), amylase, triglycerides) are subject to approval by the BIPI clinical monitor. Cholesterol \<= 240mg/dL at the time of screening is necessary for study entry
  7. Acceptable medical history, physical examination and are required prior to entering the study
  8. Willingness to abstain from alcohol for 48 hours prior to Study Day 0 and abstain from alcohol for the duration of the study. In addition, Cabernet Sauvignon must not have been ingested within 15 days prior to Day 0 (Visit 2)
  9. Willingness to abstain from ingesting grapefruit and grapefruit juice within 15 days of Day 0, Visit 2 and for the duration of the study
  10. Willingness to abstain from ingesting Seville oranges, strawberries or strawberry extract, garlic supplements, St. John's Wort, Milk Thistle, or methylxanthine-containing drinks or food (coffee, tea, cola, energy drinks, chocolate, etc) within 72 hours of pharmacokinetic (PK) sampling days
  11. Willingness to abstain from use of tobacco products for the duration of the study
  12. Urine drug screen negative for illegal non-prescription drugs
  13. Negative serology
  14. Negative for surface antigen and

Exclusion criteria

Exclusion Criteria:

  1. Female subjects who are of who:

    • Have a positive serum B-HCG at Visit 1 or 2 or
    • Have not been using regular oral (combined oestrogen and progestogen pill or progestogen only pill) for 3 months and a barrier contraceptive method for at least 30 days prior to Visit 3 (Day 1) or a barrier contraceptive method for at least 3 months prior to Visit 3 (Day 1) or
    • Are not willing to use a reliable method of double-barrier contraception (such as diaphragm with spermicidal cream/jelly or condoms with spermicidal foam)during the trial and 30 days after completion/termination or
    • Are breast-feeding
  2. Participation in another trial with an medicine for 30 days prior to Day 0 (Visit 2)
  3. Ingestion of any known enzyme altering drug (such as phenothiazines, cimetidine, barbiturates, ketoconazole, fluconazole, rifampin, , and herbal medications) for 30 days prior to Day 0 (Visit 2). Use of any other herbal/complementary treatment must be discussed in advance with the monitor and permission obtained prior to study entry
  4. Ingestion of grapefruit, grapefruit juice, and Cabernet Sauvignon within 15 days prior to Day 0 (Visit 2)
  5. Ingestion of Seville oranges, strawberries or strawberry extract, garlic supplements, St. John's Wort, Milk Thistle, or methylxanthine-containing drinks or food (coffee, tea, cola, energy drinks, chocolate, etc) within 72 hours of PK sampling days
  6. Ingestion of antibiotics within 10 days prior to Day 0 (Visit 2)
  7. Inability to comply with investigator's instructions
  8. History of gastrointestinal, hepatic, or renal disorders within 60 days
  9. History of alcohol abuse
  10. Current use of cigarettes defined as greater than 10 cigarettes per day or rolling/pipe tobacco equivalent
  11. Blood or plasma donations within 30 days prior to Day 0 (Visit 2)
  12. Subjects with a seated systolic blood pressure either \<100 mm Hg or >150 mm Hg; resting heart rate either \<50 beats/min or >100 beats/min
  13. Subjects with a history of any illness or allergy that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering tipranavir or ritonavir or tenofovir disoproxil fumarate to the subject
  14. Subjects who have had an acute illness within 2 weeks prior to Day 0 (Visit 2)
  15. Subjects who are currently taking any over-the-counter drug within 7 days prior to Day 0, (Visit 2) or who are currently taking any prescription drug that, in the opinion of the investigator in consultation with the clinical monitor and pharmacokineticist, might interfere with either the absorption, distribution or metabolism of the test substances
  16. to tipranavir, ritonavir, or tenofovir disoproxil fumarate
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    tipranavir/ritonavir low dose

    Drug: Tipranavir low dose · Drug: Ritonavir low dose · Drug: Tenofovir disoproxil fumarate

  • Experimental
    tipranavir/ritonavir high dose

    Drug: Tipranavir high dose · Drug: Ritonavir high dose · Drug: Tenofovir disoproxil fumarate

Interventions

06

What researchers measure

Primary outcomes

  1. Area under plasma concentration time curve from 0-24 hours (AUC0-24) for tenofovir

    Time frame: up to 24 hours

  2. Area under plasma concentration time curve from 0-12hours (AUC0-12) for tipranavir/ritonavir

    Time frame: up to 12 hours

  3. Maximum plasma concentration (Cmax)

    Time frame: up to 24 hours

  4. Drug concentration in plasma at 12 hours after administration (C12h) for tenofovir

    Time frame: up to 12 hours

  5. Drug concentration in plasma at 12 hours after administration (C12h) for tipranavir/ritonavir

    Time frame: up to 12 hours

Secondary outcomes

  1. Maximum plasma concentration at steady state (Cmax,ss)

    Time frame: up to 24 hours

  2. Trough plasma concentration at steady state (Cmin)

    Time frame: up to 24 hours

  3. Mean residency time (MRT)

    Time frame: up to 24 hours

  4. Apparent terminal half life (T1/2)

    Time frame: up to 24 hours

  5. Time of maximum concentration (Tmax)

    Time frame: up to 24 hours

  6. Oral clearance (CL/F)

    Time frame: up to 24 hours

  7. Apparent volume of distribution during the terminal elimination phase, divided by F (bioavailability factor) (Vz/F)

    Time frame: up to 24 hours

  8. Number of subjects with clinically significant findings in vital signs (pulse rate, blood pressure)

    Time frame: up to 14 days

  9. Number of subjects with clinically significant findings in physical examination

    Time frame: up to 14 days

  10. Number of subjects with clinically significant findings in electrocardiogram

    Time frame: up to 14 days

  11. Number of subjects with clinically significant findings in laboratory tests

    Time frame: up to 14 days

  12. Number of subjects with adverse events

    Time frame: up to 14 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2002 and a primary completion of Jun 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2014
First posted
Sep 29, 2014
Start
May 2002
Primary completionActual
Jun 2002
Last update
Sep 29, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02251145
Responsible party
Sponsor
First posted
Sep 29, 2014
Start date
May 2002
Primary completion
Jun 2002
Last update
Sep 29, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion